Trial · NCT06745323
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
NCT06745323, Phase 2, Active not recruiting, Amgen
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC. Trials, record NCT06745323. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06745323
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
- NCT number
- NCT06745323
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 252 participants, actual
- Lead sponsor
- Amgen
- Conditions
- Small Cell Lung Cancer (SCLC)
- Interventions
- Tarlatamab
- First posted
- 2024-12-20
- Last updated
- 2026-10-06
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of participants with confirmed objective response to Tarlatamab | Approximately 52 Months | |
| Primary | Proportion of participants with complete response to Tarlatamab | Approximately 52 Months | |
| Primary | Proportion of participants with partial response to Tarlatamab | Approximately 52 Months | |
| Secondary | Average serum concentrations of Tarlatamab | Approximately 52 Weeks | |
| Secondary | Duration of confirmed response, defined as the time from the first documentation of OR until the first documentation of disease progression or death | Approximately 52 Months | |
| Secondary | Disease control, defined as objective response or stable disease | Approximately 52 Months | |
| Secondary | Duration of disease control | Approximately 52 Months | |
| Secondary | Progression-free survival, defined as the time from randomization to the first documentation of disease progression or death due to any cause | Approximately 52 Months | |
| Secondary | Objective response, defined as best overall response of CR or PR | Approximately 52 Months | |
| Secondary | Overall survival, defined as the time from randomization to death due to any cause | Approximately 52 Months |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06745323
GET https://conductscience.org/api/trials/v1/NCT06745323/registered